Grand Pharmaceutical Group Ltd. Obtains Class A "Radiation Safety License" for Nuclear Medicine R&D Base, Operations to Start in June

Reuters

2025/05/18

Grand Pharmaceutical Group Ltd. Obtains Class A "Radiation Safety License" for Nuclear Medicine R&D Base, Operations to Start in June

Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Wenjiang District, Chengdu, has secured a Class A "Radiation Safety License" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&D platforms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536656109"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536656109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536656109?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-18 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536656109","market":"nz","top_or_hot":-1,"title":"Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&amp;D Base, Operations to Start in June\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&amp;D and production base in Wenjiang District, Chengdu, has secured a Class A \"Radiation Safety License\" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&amp;D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&amp;D platforms.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-18 18:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&amp;D Base, Operations to Start in June\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&amp;D and production base in Wenjiang District, Chengdu, has secured a Class A \"Radiation Safety License\" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&amp;D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&amp;D platforms.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250518:nNDL6DW2Yw:1","article_id":"2536656109","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536656109","pubTimestamp":1747564292,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June. Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Wenjiang District, Chengdu, has secured a Class A \"Radiation Safety License\" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&D platforms.Disclaimer: This news brief was created by Public Technologies","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD","BK1191":"制药","00512":"远大医药","BK7067":"生物科技"},"translate_title":"远大医药集团核医学研发基地获得A类“辐射安全许可证”6月开始运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9,"00512":0.9},"content_text":"Grand Pharmaceutical Group Ltd. Obtains Class A \"Radiation Safety License\" for Nuclear Medicine R&D Base, Operations to Start in June\n    \n\n        Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Wenjiang District, Chengdu, has secured a Class A \"Radiation Safety License\" from the Ministry of Ecology and Environment of China. This significant regulatory approval will allow the facility to commence operations in June. The base, which began construction in late 2022, has achieved rapid development milestones, breaking industry construction records. This facility is integral to Grand Pharmaceutical's strategic expansion in the fields of R&D, production, and sales of advanced anti-tumor technologies. The Group collaborates with organizations such as Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited to enhance its tumor intervention and radionuclide-drug conjugate R&D platforms.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}